Ipamorelin (5mg)

Ipamorelin Peptide Overview
Ipamorelin, a pentapeptide composed of five amino acids, is recognized as a ‘growth hormone secretagogue.’ While its mechanism of action primarily involves ghrelin receptor binding, the precise details of its interactions are still subjects of ongoing investigation in scientific research. Classified as a growth hormone secretagogue (GHS-R), Ipamorelin peptide shows promise in the regulation of energy balance and weight. This synthetic peptide shares potential similarities with growth hormones (HGH). Through various research studies and laboratory assessments, Ipamorelin has been identified as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with the ability to stimulate the pituitary gland, thereby initiating the release of growth hormones.

Ipamorelin Peptide Mechanism of Action
Ipamorelin stands out as the initial synthetic growth hormone secretagogue, displaying the capability to enhance the natural production of growth hormone.⁽³⁾ Distinguished by its notable selectivity for growth receptors in the gland, Ipamorelin shares similarities with growth hormone receptor peptide (GHRP) receptor agonists. Its potential to bind with GHRP receptors may facilitate the secretion and potential amplification of growth hormone production, presenting a distinct mechanism of action.

Multiple research studies have indicated that Ipamorelin, unlike other hormones stimulating human growth hormone (HGH), may not notably elevate the levels of cortisol and Adrenocorticotropic (ACH) hormones in the bloodstream. This suggests that Ipamorelin could be characterized as a GHRP-receptor agonist with heightened selectivity for the release of growth hormone, potentially exerting its effects without significant impact on ACH and cortisol levels.

Scientific Investigations and Clinical Trials

Ipamorelin Peptide and Early Investigations
In a study conducted in 1998, the administration of Ipamorelin to rats demonstrated the potential to induce the release of growth hormones from pituitary cells. When administered to swine and rats under pentobarbitone anesthesia, Ipamorelin reportedly triggered the release of growth hormones. The researchers inferred that Ipamorelin, akin to other growth hormone (GH) stimulating peptides, might function as a growth receptor agonist, potentially stimulating the release of GH by interacting with growth hormone receptors.⁽³⁾

In 1999, further investigations were conducted on adult female rats, exposing them to Ipamorelin three times daily. After a 15-day period following delivery, researchers proposed that the levels of growth hormones were seemingly heightened. Additionally, the longitudinal bone growth rate (LGR) exhibited an apparent increase, rising from 42 micrometers per day to as much as 52 micrometers per day, according to the findings by the scientists.⁽⁴⁾

In the latter part of 1999, a clinical trial involving 8 male participants was conducted, administering Ipamorelin at 15-minute intervals for a specified duration. The researchers reported that, following the study, the levels of growth hormones had seemingly experienced a significant and exponential increase, reaching their highest peak within a single administration of the peptide after 2 hours.⁽⁵⁾

Clinical Studies on Ipamorelin and Growth Hormone Deficiencies
From 2001 onwards, numerous clinical studies have explored the effects of growth hormone releasing peptides on individuals with growth hormone deficiency. These peptides, including Ipamorelin, have demonstrated potential in stimulating the pituitary gland for growth hormone release and possibly acting on the arcuate nucleus of the hypothalamus. Although these peptides have shown the ability to induce significant releases of growth hormones, the specific mechanism, whether through pituitary gland stimulation or hypothalamic action, remains unclear.⁽⁶⁾

In a study involving six individuals experiencing growth hormone deficiency and growth failure, graded concentrations of Ipamorelin were administered over an eight-month period. Monitoring occurred every 12 hours to assess episodic growth hormone secretion and toxicity levels. Results after two months indicated a noticeable surge in growth hormone levels among the subjects during the trial, with minimal impact on GH levels observed in the later stages of the study.⁽⁷⁾

Ipamorelin peptide is exclusively intended for research and laboratory applications. Prior to making a purchase, it is essential to carefully review and comply with our Terms and Conditions to ensure adherence to the specified guidelines and regulations governing its use.